TEVA ▼ -0.5% - Teva Pharmaceutical Industries Limited $TEVA - Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs Teva Pharmaceutical Industries fell 0.5% today following the release of real-world data demonstrating that its UZEDY risperidone injection outperforms competing long-acting injectable antipsychotics in treatment adherence, emergency department visits, and overall healthcare costs for schizophrenia patients. The modest decline suggests the market may have already priced in positive developments for the drug or investors are waiting for additional clinical or commercial validation before committing to a larger move. 18-SEP-2026 04:31 PM ET